Raymond James Boosts UnitedHealth (UNH) Rating Before Q1 Results

Key Takeaways

• First-quarter earnings from UnitedHealth (UNH) scheduled for April 21, 2026
• Consensus estimates point to $6.69 EPS, reflecting an 8% year-over-year drop, alongside $109.58 billion in revenue
• Raymond James raised its rating to Outperform, establishing a $330 target price
• Shares climbed approximately 1.2% in response to the analyst action
• Derivatives markets suggest a potential ~9% swing following the earnings announcement

UnitedHealth Group prepares to unveil its first-quarter financial performance on April 21, with market participants paying close attention following a challenging beginning to 2026.

UnitedHealth Group Incorporated, UNH

Shares have tumbled approximately 17% year-to-date, weighed down by disappointing forward guidance and persistent challenges within its Medicare Advantage segment. This selloff has pushed the stock beneath the entry point established by Berkshire Hathaway, igniting discussion about potential value at current levels.

The Street anticipates adjusted earnings per share of $6.69 for the quarter, representing an 8% decline compared to the prior-year period. Revenue projections stand at $109.58 billion, essentially unchanged from last year’s figure.

Options activity suggests traders are bracing for approximately 9% volatility in either direction once results are published — indicating heightened uncertainty surrounding the upcoming release.

On April 1, Raymond James elevated UNH from Market Perform to Outperform, assigning a $330 price objective. Analyst John Ransom contended that the market is overlooking the company’s earnings capacity, especially regarding operational efficiency gains.

The rating change propelled shares higher by roughly 1.2% during the April 2 session, with the stock touching $279.04 before closing at $277.30.

Ransom highlighted administrative expense optimization as a crucial catalyst. His analysis suggests that each 100-basis-point reduction in general and administrative costs could contribute approximately $3.80 to per-share earnings.

Optum Health Under the Microscope

Raymond James noted enhanced transparency around Optum Health’s margin profile. While current-year margins may appear stable, the firm believes the underlying trajectory is favorable as UnitedHealth divests from loss-making assets.

The healthcare giant has already shuttered or divested multiple unprofitable clinic locations. This rationalization effort should alleviate margin compression moving forward.

Optum’s fee-for-service operations, generating approximately $33 billion annually, currently operate at single-digit profitability. Analysts identify substantial improvement potential through enhanced operational discipline.

The collective Wall Street sentiment toward UNH skews positive. According to TipRanks analytics compiled April 1, the stock carries a “Strong Buy” rating based on 17 Buy recommendations, 3 Hold ratings, and no Sell calls.

The consensus 12-month price objective stands at $366.47, suggesting approximately 35% appreciation potential from current trading levels. The most optimistic forecast envisions UNH at $440, while the most conservative projection sits at $311.

Potential Headwinds Persist

Some analysts maintain caution. Leerink identified Risk Adjustment Data Validation (RADV) audits — Medicare Advantage payment reconciliations — as a significant challenge.

An upcoming Ninth Circuit Court decision regarding UnitedHealth’s preemption argument could broaden legal exposure should the ruling prove unfavorable.

Institutional investors control approximately 87.9% of outstanding shares. Major stakeholders include Norges Bank, Capital Research Global Investors, Berkshire Hathaway, and Dodge & Cox, which substantially increased its holdings in the previous year.

Notwithstanding the 2026 downturn, UNH recently secured a position among the top 10 holdings within the Schwab U.S. Dividend Equity ETF. The corporation distributes an annual dividend of $8.84 per share, currently yielding about 3.2%.

The most recent quarterly report showed a modest earnings beat — $2.11 EPS against the $2.09 Street estimate — accompanied by $113.73 billion in revenue, reflecting 12.3% year-over-year growth.

First-quarter financial results will be released prior to the market opening on April 21.